HIGHLIGHTS
- who: Luying Wan and colleagues from the Department of Oncology, Molecular Oncology Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China have published the article: Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors, in the Journal: Disease Markers 7 of 23/Dec/2022
- how: The results indicated that increased LMR at baseline was associated with a superior OS (HR 0.46 95% CI Posttreatment LMR was linked to a better PFS (HR 0.46 95% CI 0.29-0.71 p = 0001) but failed to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.